{"groups":[{"description":"Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.\n\nCyclophosphamide: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeukapheresis: Undergo leukapheresis\n\nTGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes: Given IV at 1 x 10\\^7","id":"FG000","title":"Cohort 1 (Cyclophosphamide, TCR/dnTGFbetaRII - Dose Level 1)"},{"description":"Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.\n\nCyclophosphamide: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeukapheresis: Undergo leukapheresis\n\nTGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes: Given IV at 1 x 10\\^8","id":"FG001","title":"Cohort 2 (Cyclophosphamide, TCR/dnTGFbetaRII - Dose Level 2)"},{"description":"Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.\n\nCyclophosphamide: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeukapheresis: Undergo leukapheresis\n\nTGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes: Given IV at 1 x 10\\^9","id":"FG002","title":"Cohort 3 (Cyclophosphamide, TCR/dnTGFbetaRII - Dose Level 3)"},{"description":"Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.\n\nCyclophosphamide: Given IV\n\nDecitabine: Given IV at 20 mg/m\\^2 x 3 days\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeukapheresis: Undergo leukapheresis\n\nTGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes: Given IV at 1 x 10\\^9","id":"FG003","title":"Cohort 4 (Decitabine, Cyclophosphamide, TCR/dnTGFbetaRII - Dose Level 3)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}